

Dear Reader,

As we reach the final issue of *Drugs in R&D* for 2012, we hope you have found the articles published throughout the year to be interesting and informative. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in the field of research and development in 2013.

Following the acquisition of the Adis journals at the end of last year by Springer Science+Business Media, we have been working to transition the production and fulfillment of the Adis journals into Springer processes. This integration will be complete by the end of 2012, such that production and delivery of all Adis journals will be fully transitioned for the first issues of 2013. Adis journal content will be available on a new and improved online platform.

We are pleased that Springer has decided to keep the Adis brand and recognizes the core values that the brand represents. We are confident that the association with Springer will lead to increased awareness and usage of Adis content, further driving impact factors and recognition. Collectively, we feel that the future for Adis looks bright, and we are happy with the acquisition by Springer.

The high quality of Adis Journals was acknowledged in the new ISI impact factors for 2011, with the majority of our titles making gains over 2010. The most impressive gains were made by *Clinical Pharmacokinetics* (5.398), with a 19.6% increase, *Drugs* (4.226), which increased by 13%, and *Clinical Drug Investigation* (1.822), an increase of 12.3% over 2010. Two of our journals received their first impact factors in 2011 – *Pediatric Drugs*, with an impact factor of 1.786, and *The Patient* (0.571).

We would like to say a big thank you to all of the authors who have contributed articles to *Drugs in R&D* within the last 12 months. Without their hard work and diligence, we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals, who acted as referees for articles in *Drugs in R&D* in 2012:

Albert Adell, Spain
Ali Alikhan, USA
Robert J. Amato, USA
Soo Kyung Bae, Republic of Korea
Luis Bahamondes, Brazil
Bernard Bannwarth, France
Marcelo C. Bertolami, Brazil

Joseph M. Blondeau, Canada
Nichola Boyle, Australia
Peter Bramlage, Germany
Yong Chen, USA
Victor Chuang, Australia
Daniel F. Connor, USA
Gilberto De Nucci, Brazil

Sheila A. Doggrell, Australia
Santiago Ewig, Germany
David N. Franz, USA
David J. Greenblatt, USA
Ganesh V. Halade, USA
Sanjeev Handa, India
Klaas A. Hartholt, the Netherlands
Daniel E. Hilleman, USA
Gabor Hollo, Hungary
Li Huafang, China
Atsuko A. Inoue, Japan
Makoto Ishikawa, Japan
Hartmut Jaeschke, USA
Joetta M. Juenke, USA
Menelaos Karanikolas, Greece
Kiyoshi Kikuchi, Japan
Gideon Koren, Canada
Paul A. Lapchak, USA
Leonard Liebes, USA
Charles L. Loprinzi, USA
Gianluca Manni, Italy
Robert Mathie, UK
Andrew J. McLachlan, Australia
Andrei V. Medvedovici, Romania
Marco Montillo, Italy
F. Marcel Musteata, USA
Samar Muwakkil, Lebanon
Taizen Nakase, Japan
Hiroaki Naritomi, Japan
Michinori Ogura, Japan
Muge G. Ozden, Turkey

Girolamo Pelaia, Italy
Rita Pichardo, USA
Charalampos Pierrakos, Belgium
Simon W. Rabkin, Canada
Alex Rawlinson, UK
Claire Relton, UK
James L. Roerig, USA
Menachem Rottem, Israel
Brian B.H. Rowe, Canada
Barry Rumack, USA
A. Oliver Sartor, USA
Bancha Satirapoj, Thailand
Rashmi R. Shah, UK
Manuel Sosa, Spain
Carlos Sostres, Spain
Motohiro Tamiya, Japan
Joel Tarning, Thailand
Michael E. Thase, USA
Sadao Tokimasa, Japan
Chaitra S. Ujjani, USA
Giuseppe Visani, Italy
Mari Wataya-Kaneda, Japan
Ping Wei, China
Paul Welsh, UK
William N. William Jr., USA
Johannes Wohlrab, Germany
Cory Yamashita, Canada
Takashi Yamashita, USA
Abdel N. Zaid, Palestinian Territory
Xiangjian Zhang, China
Yan Zhang, USA

We look forward to your continued support of the journal in 2013 and to bringing you first-class content from around the globe.

Best wishes from the staff of *Drugs in R&D* and all at Adis Publications.